Mesothelioma: your questions and future treatment options

Susie Harden 1/4/11Susie Harden 1/4/11

Future possibilities in Cambridge

First line studiesFirst line studies Second line studiesSecond line studies Phase 1 studiesPhase 1 studies Biobank: potential for individually tailored Biobank: potential for individually tailored

treatments in the future?treatments in the future?

First line studies coming soon

MESO 2: phase II study of adding MESO 2: phase II study of adding vorinostat to pemetrexed /cisplatin vorinostat to pemetrexed /cisplatin [this agent is a histone deacetylase inhibitor and acts to [this agent is a histone deacetylase inhibitor and acts to ‘unblock’ certain genes in tumour cells ‘unblock’ certain genes in tumour cells

ADAM: Phase II study of pegylated ADAM: Phase II study of pegylated arginine deaminase/placebo arginine deaminase/placebo [when chemotherapy not indicated in ASS (arginosuccinate [when chemotherapy not indicated in ASS (arginosuccinate synthetase) negative patients. (this agent depletes tumours synthetase) negative patients. (this agent depletes tumours of an essential amino acid – arginine)]of an essential amino acid – arginine)]

Secondline studies

No standard treatment but re-challenge with No standard treatment but re-challenge with pemetrexed if good first time response pemetrexed if good first time response acceptedaccepted

No imminent trials in CambridgeNo imminent trials in Cambridge

Phase 1 studies in Cambridge

S222611 SHINOGIS222611 SHINOGI[a dual EGFR and HER2 small molecule inhibitor][a dual EGFR and HER2 small molecule inhibitor]

Radiotherapy (your feedback please!)Radiotherapy (your feedback please!)

Tomotherapy dose-wash diagram

Over to you!

Any questions?Any questions?

Any suggestions?Any suggestions?